How much revenue does Tonghua Golden-Horse Pharmaceutical Industry make?

Tonghua Golden-Horse Pharmaceutical Industry reported 1.32 billion CNY in revenue for fiscal year 2024, down 10.2% from 1.47 billion CNY in fiscal year 2023. In Q2 2025 revenue was 350.70 million CNY.

What companies are similar to Tonghua Golden-Horse Pharmaceutical Industry?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ), Joincare Pharmaceutical Group Industry Co.,Ltd. (600380.SS), ApicHope Pharmaceutical Group Co., Ltd. (300723.SZ), Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS).

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ) Stock

About Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical products in China. The company provides anti-tumor drugs, gynecological medications, medication for rheumatic bone pain, urological medications, heat-clearing and detoxifying drugs, cardiovascular and cerebrovascular drugs, digestive me...

At a glance

Tonghua Golden-Horse Pharmaceutical Industry reported revenue of 1.32 billion CNY for fiscal year 2024, down 10.2% from fiscal year 2023, and net income of 56.44 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 350.70 million CNY, down 0.8% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.